Karyopharm Therapeutics Inc. — Q1 2016 Form 10-Q
Business context and reporting period
Unaudited results cover the three months ended March 31, 2016; balance-sheet comparisons are to December 31, 2015. Karyopharm is a clinical-stage pharmaceutical company developing SINE compounds that inhibit XPO1. Its lead candidate, selinexor, is being studied in hematologic cancers and solid tumors. The company reported no revenue from drug sales.
Financial results and liquidity
| Metric | Q1 2016 | Q1 2015 / prior date |
|---|---|---|
| Research and development expense | $21.8 million | $20.8 million |
| General and administrative expense | $5.6 million | $5.4 million |
| Total operating expenses | $27.3 million | $26.2 million |
| Operating loss | $27.3 million | $26.2 million |
| Net loss | $27.1 million | $26.1 million |
| Basic and diluted loss per share | $0.75 | $0.74 |
| Net cash used in operating activities | $23.2 million | $20.2 million |
| Cash and cash equivalents | $42.2 million | $58.4 million at Dec. 31, 2015 |
| Short- and long-term investments | $144.4 million | $151.2 million at Dec. 31, 2015 |
| Total assets | $192.1 million | $215.4 million at Dec. 31, 2015 |
Including restricted cash, cash, cash equivalents and investments totaled $187.1 million at quarter-end. Current assets were $138.1 million and current liabilities $13.2 million; no borrowings or debt balance is reported in the supplied financial statements. The company has no meaningful revenue or gross margin to report. It reported an accumulated deficit of $283.6 million.
Changes versus the prior comparable period
- Net loss increased by $1.0 million, or about 4%; operating expenses rose 5% year over year.
- R&D expense increased $1.0 million. Higher personnel and stock-based compensation costs, and increased selinexor trial costs, were partly offset by lower preclinical study and consulting costs.
- G&A expense increased $0.2 million, mainly reflecting personnel and stock-based compensation, partly offset by lower consulting and professional costs.
- Operating cash use increased $2.9 million year over year. Financing cash inflow was only $0.2 million in Q1 2016, versus $91.2 million in Q1 2015, when the company received proceeds from an equity offering.
- Cash and cash equivalents declined $16.2 million during Q1 2016. Investment purchases and maturities were the main investing cash flows; they do not represent operating cash generation.
Outlook, risks and other notable items
- Management expected existing cash, cash equivalents and investments to fund the current operating plan and capital needs into mid-2018, and projected more than $120 million in cash, cash equivalents, restricted cash and investments at year-end 2016. These are management estimates, not assurances; funding needs depend on clinical progress, costs and other factors.
- Management expected R&D and G&A expenses to remain consistent for the rest of 2016, while also warning that expenses and operating losses were expected to rise over the longer term as development and potential commercialization advanced. Additional funding will be needed; none was committed.
- The company reported a randomized Phase 2/3 selinexor study in liposarcoma and expected to initiate a selinexor/carfilzomib/dexamethasone study for multiple myeloma in mid-2016. Trial outcomes, enrollment, regulatory decisions and safety remain substantial uncertainties.
- Disclosed selinexor safety concerns include possible worsening of pre-existing cataracts; common drug-related events included gastrointestinal effects and fatigue, with Grade 3 or 4 thrombocytopenia and neutropenia among the more common severe events. The company also noted increased sepsis rates in AML patients receiving higher doses.
- Other material risks include clinical failure or delays, dependence on third-party trial and manufacturing providers, competition, patent and regulatory uncertainty, and the need to obtain financing. The company reported no off-balance-sheet arrangements and no material change to contractual obligations described in its 2015 Form 10-K.
- Management concluded disclosure controls and procedures were effective at the reasonable-assurance level as of March 31, 2016; no material change in internal control over financial reporting was reported during the quarter.
Important facts for investors to verify
- Current enrollment, timing, endpoints and results for selinexor trials, especially the liposarcoma Phase 2/3 study and planned multiple myeloma combination study.
- Whether the stated mid-2018 cash runway and year-end 2016 liquidity expectation remain achievable, given the quarterly operating cash burn and future trial spending.
- Updated safety data, including cataract effects, severe blood-count events and sepsis observations in higher-dose AML patients.
- Progress toward regulatory approval and commercialization, and the potential costs and funding required to support those plans.
- Use of the available $50 million at-the-market equity program and the dilution implications of any future financing.